Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 298

1.

Screening for Epstein-Barr virus (EBV) infection status in university freshmen: acceptability of a gingival swab method.

Grimm-Geris JM, Dunmire SK, Duval LM, Filtz EA, Leuschen HJ, Schmeling DO, Kulasingam SL, Balfour HH.

Epidemiol Infect. 2019 Jan;147:e140. doi: 10.1017/S0950268819000335.

2.

Epstein-Barr Virus DNA in Parental Oral Secretions: A Potential Source of Infection for Their Young Children.

Cederberg LE, Rabinovitch MD, Grimm-Geris JM, Schmeling DO, Filtz EA, Condon LM, Balfour HH Jr.

Clin Infect Dis. 2019 Jan 7;68(2):306-312. doi: 10.1093/cid/ciy464.

PMID:
29846551
3.

Primary Epstein-Barr virus infection.

Dunmire SK, Verghese PS, Balfour HH Jr.

J Clin Virol. 2018 May;102:84-92. doi: 10.1016/j.jcv.2018.03.001. Epub 2018 Mar 5. Review.

PMID:
29525635
4.

Transplantation of solid organ recipients shedding Epstein-Barr virus DNA pre-transplant: A prospective study.

Verghese PS, Schmeling DO, Filtz EA, Grimm JM, Matas AJ, Balfour HH Jr.

Clin Transplant. 2017 Nov;31(11). doi: 10.1111/ctr.13116. Epub 2017 Oct 8.

PMID:
28915342
5.

The impact of recipient BKV shedding before transplant on BKV viruria, DNAemia, and nephropathy post-transplant: A prospective study.

Verghese PS, Schmeling DO, Filtz EA, Matas AJ, Balfour HH Jr.

Pediatr Transplant. 2017 Aug;21(5). doi: 10.1111/petr.12942. Epub 2017 May 29.

6.

Prospective studies of infectious mononucleosis in university students.

Grimm JM, Schmeling DO, Dunmire SK, Knight JA, Mullan BD, Ed JA, Brundage RC, Hogquist KA, Balfour HH Jr.

Clin Transl Immunology. 2016 Aug 12;5(8):e94. doi: 10.1038/cti.2016.48. eCollection 2016 Aug.

7.

Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study.

Johnson KH, Webb CH, Schmeling DO, Brundage RC, Balfour HH Jr.

Clin Transl Immunology. 2016 May 13;5(5):e81. doi: 10.1038/cti.2016.28. eCollection 2016 May.

8.

Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Bu W, Hayes GM, Liu H, Gemmell L, Schmeling DO, Radecki P, Aguilar F, Burbelo PD, Woo J, Balfour HH Jr, Cohen JI.

Clin Vaccine Immunol. 2016 Apr 4;23(4):363-9. doi: 10.1128/CVI.00674-15. Print 2016 Apr.

9.

The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events.

Dunmire SK, Grimm JM, Schmeling DO, Balfour HH Jr, Hogquist KA.

PLoS Pathog. 2015 Dec 1;11(12):e1005286. doi: 10.1371/journal.ppat.1005286. eCollection 2015 Dec.

10.

Coprevalence of Epstein-Barr Virus, Cytomegalovirus, and Herpes Simplex Virus Type-1 Antibodies Among United States Children and Factors Associated With Their Acquisition.

Delaney AS, Thomas W, Balfour HH Jr.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):323-9. doi: 10.1093/jpids/piu076. Epub 2014 Jul 17.

PMID:
26582871
11.

Infectious Mononucleosis.

Dunmire SK, Hogquist KA, Balfour HH.

Curr Top Microbiol Immunol. 2015;390(Pt 1):211-40. doi: 10.1007/978-3-319-22822-8_9. Review.

12.

B cell-derived circulating granzyme B is a feature of acute infectious mononucleosis.

Hagn M, Panikkar A, Smith C, Balfour HH Jr, Khanna R, Voskoboinik I, Trapani JA.

Clin Transl Immunology. 2015 Jun 26;4(6):e38. doi: 10.1038/cti.2015.10. eCollection 2015 Jun.

13.

Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell Dysfunction.

Panikkar A, Smith C, Hislop A, Tellam N, Dasari V, Hogquist KA, Wykes M, Moss DJ, Rickinson A, Balfour HH Jr, Khanna R.

J Virol. 2015 Sep;89(17):9137-41. doi: 10.1128/JVI.01293-15. Epub 2015 Jun 24.

14.

Cytokine-Mediated Loss of Blood Dendritic Cells During Epstein-Barr Virus-Associated Acute Infectious Mononucleosis: Implication for Immune Dysregulation.

Panikkar A, Smith C, Hislop A, Tellam N, Dasari V, Hogquist KA, Wykes M, Moss DJ, Rickinson A, Balfour HH Jr, Khanna R.

J Infect Dis. 2015 Dec 15;212(12):1957-61. doi: 10.1093/infdis/jiv340. Epub 2015 Jun 16.

PMID:
26080368
15.

Infectious mononucleosis.

Balfour HH Jr, Dunmire SK, Hogquist KA.

Clin Transl Immunology. 2015 Feb 27;4(2):e33. doi: 10.1038/cti.2015.1. eCollection 2015 Feb. Review.

16.

Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.

Verghese PS, Schmeling DO, Knight JA, Matas AJ, Balfour HH Jr.

Transplantation. 2015 Jun;99(6):1186-91. doi: 10.1097/TP.0000000000000490.

PMID:
25489844
17.

The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.

Verghese PS, Schmeling DO, Knight JA, Matas AJ, Balfour HH Jr.

Transplantation. 2015 Mar;99(3):602-8. doi: 10.1097/TP.0000000000000354.

18.

EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.

Hart M, Thakral B, Yohe S, Balfour HH Jr, Singh C, Spears M, McKenna RW.

Am J Surg Pathol. 2014 Nov;38(11):1522-9. doi: 10.1097/PAS.0000000000000282.

PMID:
25007145
19.

Age-specific prevalence of Epstein-Barr virus infection among Minnesota children: effects of race/ethnicity and family environment.

Condon LM, Cederberg LE, Rabinovitch MD, Liebo RV, Go JC, Delaney AS, Schmeling DO, Thomas W, Balfour HH Jr.

Clin Infect Dis. 2014 Aug 15;59(4):501-8. doi: 10.1093/cid/ciu342. Epub 2014 May 11.

PMID:
24820696
20.

Cutting edge: NKG2C(hi)CD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus.

Hendricks DW, Balfour HH Jr, Dunmire SK, Schmeling DO, Hogquist KA, Lanier LL.

J Immunol. 2014 May 15;192(10):4492-6. doi: 10.4049/jimmunol.1303211. Epub 2014 Apr 16.

21.

Editorial commentary: Genetics and infectious mononucleosis.

Balfour HH Jr.

Clin Infect Dis. 2014 Jun;58(12):1690-1. doi: 10.1093/cid/ciu206. Epub 2014 Apr 2. No abstract available.

22.

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Balfour HH Jr.

Curr Opin Virol. 2014 Jun;6:1-5. doi: 10.1016/j.coviro.2014.02.005. Epub 2014 Mar 15. Review.

23.

Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.

Vezina HE, Brundage RC, Balfour HH Jr.

Br J Clin Pharmacol. 2014 Aug;78(2):343-52. doi: 10.1111/bcp.12343.

24.

Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes.

Dunmire SK, Odumade OA, Porter JL, Reyes-Genere J, Schmeling DO, Bilgic H, Fan D, Baechler EC, Balfour HH Jr, Hogquist KA.

PLoS One. 2014 Jan 17;9(1):e85422. doi: 10.1371/journal.pone.0085422. eCollection 2014.

25.

The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.

Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, Mikulski Z, Shaheen ZR, Cheng G, Sawatzke K, Campbell AM, Auger JL, Bilgic H, Shoyama FM, Schmeling DO, Balfour HH Jr, Hasegawa K, Chan AC, Corbett JA, Binstadt BA, Mescher MF, Ley K, Bottini N, Peterson EJ.

Immunity. 2013 Jul 25;39(1):111-22. doi: 10.1016/j.immuni.2013.06.013. Epub 2013 Jul 18.

26.

Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition.

Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W.

J Infect Dis. 2013 Oct 15;208(8):1286-93. doi: 10.1093/infdis/jit321. Epub 2013 Jul 18.

PMID:
23868878
27.

Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.

Choi KY, Sharon B, Balfour HH Jr, Belani K, Pozos TC, Schleiss MR.

J Clin Virol. 2013 Aug;57(4):356-60. doi: 10.1016/j.jcv.2013.04.004. Epub 2013 May 18.

28.

Primary Epstein-Barr virus infection: impact of age at acquisition, coinfection, and viral load.

Balfour HH Jr, Verghese P.

J Infect Dis. 2013 Jun 15;207(12):1787-9. doi: 10.1093/infdis/jit096. Epub 2013 Mar 14. No abstract available.

29.

Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.

Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA.

J Infect Dis. 2013 Jan 1;207(1):80-8. doi: 10.1093/infdis/jis646. Epub 2012 Oct 24. Erratum in: J Infect Dis. 2013 Jun 15;207(12):1940.

30.

Primary Epstein-Barr virus infection does not erode preexisting CD8⁺ T cell memory in humans.

Odumade OA, Knight JA, Schmeling DO, Masopust D, Balfour HH Jr, Hogquist KA.

J Exp Med. 2012 Mar 12;209(3):471-8. doi: 10.1084/jem.20112401. Epub 2012 Mar 5.

31.

Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.

Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH Jr.

Clin Transplant. 2012 Sep-Oct;26(5):741-7. doi: 10.1111/j.1399-0012.2012.01608.x. Epub 2012 Mar 4.

32.

Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Odumade OA, Hogquist KA, Balfour HH Jr.

Clin Microbiol Rev. 2011 Jan;24(1):193-209. doi: 10.1128/CMR.00044-10. Review.

33.

The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.

Markowitz M, Vaida F, Hare CB, Boden D, Mohri H, Hecht FM, Kalayjian RC, Conrad A, Mildvan D, Aberg J, Hogan C, Kilby JM, Balfour HH Jr, Schafer K, Richman D, Little S.

J Infect Dis. 2010 May 1;201(9):1298-302. doi: 10.1086/651664.

34.

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein-Barr virus disease.

Vezina HE, Brundage RC, Nevins TE, Balfour HH Jr.

Clin Pharmacol. 2010;2:1-7. doi: 10.2147/CPAA.S8341. Epub 2009 Dec 22.

35.

Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.

Vezina HE, Balfour HH Jr, Weller DR, Anderson BJ, Brundage RC.

J Clin Pharmacol. 2010 Jul;50(7):734-42. doi: 10.1177/0091270009351884. Epub 2009 Nov 6.

36.
37.

Coinfection alters the playing field: herpesviruses induce acyclovir to inhibit HIV.

Stapleton JT, Balfour HH Jr.

Cell Host Microbe. 2008 Sep 11;4(3):194-5. doi: 10.1016/j.chom.2008.08.006.

38.

Epstein-Barr virus vaccine for the prevention of infectious mononucleosis--and what else?

Balfour HH Jr.

J Infect Dis. 2007 Dec 15;196(12):1724-6. doi: 10.1086/523815. No abstract available.

PMID:
18190249
39.

Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus.

Hayden RT, Hokanson KM, Pounds SB, Bankowski MJ, Belzer SW, Carr J, Diorio D, Forman MS, Joshi Y, Hillyard D, Hodinka RL, Nikiforova MN, Romain CA, Stevenson J, Valsamakis A, Balfour HH Jr; U.S. EBV Working Group.

J Clin Microbiol. 2008 Jan;46(1):157-63. Epub 2007 Nov 7.

40.

A virologic pilot study of valacyclovir in infectious mononucleosis.

Balfour HH Jr, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage RC.

J Clin Virol. 2007 May;39(1):16-21. Epub 2007 Mar 21.

PMID:
17369082
41.

An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

Weller DR, Brundage RC, Balfour HH Jr, Vezina HE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):369-73. Epub 2006 Nov 1.

PMID:
17081812
42.

A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.

Vezina HE, Henry K, Ravindran GD, Kurpad AV, Raj TD, Fox K, Weller D, Brundage RC, Cavert W, Balfour HH Jr.

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):131-6.

PMID:
16394842
43.

A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis.

Balfour HH Jr, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, White DR, Schmeling DO, Webb CH, Cavert W, Wang DH, Brundage RC.

J Infect Dis. 2005 Nov 1;192(9):1505-12. Epub 2005 Sep 26.

PMID:
16206064
44.
45.

Detection of antiretroviral resistance in HIV-1.

Cavert W, Balfour HH Jr.

Clin Lab Med. 2003 Dec;23(4):915-28. Review.

PMID:
14711099
46.

Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1.

Acosta EP, Balfour HH Jr.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):343-8.

PMID:
12843745
47.

Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.

Julin JE, van Burik JH, Krivit W, Webb C, Holman CJ, Clark HB, Balfour HH Jr.

Transpl Infect Dis. 2002 Dec;4(4):201-6.

PMID:
12535263
48.

Specific detection of human BK polyomavirus in urine samples of immunocompromised patients.

Holman CJ, van Burik JA, Hinrichs SH, Balfour HH Jr.

Clin Diagn Lab Immunol. 2003 Jan;10(1):66-9.

49.

Lymphocyte mitochondrial biomarkers in asymptomatic HIV-1-infected individuals treated with nucleoside reverse transcriptase inhibitors.

Henry K, Erice A, Balfour HH Jr, Schmeling M, Berthiaume J, Wallace K.

AIDS. 2002 Dec 6;16(18):2485-7. No abstract available.

PMID:
12461427
50.

Predictive value of HIV-1 viral load on risk for opportunistic infection.

Swindells S, Evans S, Zackin R, Goldman M, Haubrich R, Filler SG, Balfour HH Jr; AIDS Clinical Trial Group 722 Study Team.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):154-8.

PMID:
12045677

Supplemental Content

Loading ...
Support Center